M. Duruisseaux

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

M. Duruisseaux, Anna Martínez‐Cardús, María Eréndira Calleja-Cervantes et al. · The Lancet Respiratory Medicine · 2018 · 222 citations · Full text

Medicine, Oncology, Epigenetics +16

Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma

Thibault Vieira, Nicolas Girard, Mony Ung et al. · Journal of Thoracic Oncology · 2013 · 203 citations · Full text

Medicine, Oncology, Pharmacology +7

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

Shirish M. Gadgeel, Alice T. Shaw, Ramaswamy Govindan et al. · Journal of Clinical Oncology · 2016 · 196 citations · Full text

Medicine, Oncology, Pharmacology +14

Overall survival with crizotinib and next-generation ALK inhibitors in <i>ALK</i>-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

M. Duruisseaux, Benjamin Besse, J. Cadranel et al. · Oncotarget · 2017 · 162 citations · Full text

Medicine, Oncology, Pharmacology +14

Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages

Thibault Vieira, Martine Antoine, Cécile Hamard et al. · Lung Cancer · 2016 · 140 citations · Full text

Medicine, Immunology, Oncology +17